UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Set To Challenge Humira In Skin Disease
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.
